BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GSK4527363 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GSK4527363\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06576271-5646@assetmemo.bio
DTSTAMP:20261121T004954Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:GSK4527363: Phase 1 readout est. (NCT06576271)
DESCRIPTION:GSK4527363\, phase 1\, Systemic Lupus Erythematosus.\nStudy: A 
 Study of GSK4527363 in Healthy Participants\, Systemic Lupus Erythematosus
  (SLE) Participants\, Healthy Chinese\, and Japanese Participants and CTD-
 ILD Participants\nEstimated primary completion: 1 February 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/gsk4527363#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06576271
URL:https://assetmemo.bio/drug/gsk4527363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
